Suggested remit: To appraise the clinical and cost-effectiveness of catumaxomab within its marketing authorisation for treating malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6580
Provisional Schedule
- Committee meeting:
- 10 June 2026
- Expected publication:
- 30 September 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Pharmanovia (catumaxomab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- AMEND
- AMMF – The Cholangiocarcinoma Charity
- Black Health Agency for Equality
- Bob Champion Cancer Trust
- Bowel Cancer UK
- Breast Cancer Now
- Breast Cancer UK
- British liver Trust
- Butterfly Thyroid Cancer Trust
- Cancer Black Care
- Cancer52
- Eve Appeal
- Fight Bladder Cancer
- GIST Cancer UK
- Go Girls
- Guts UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Inflammatory Breast Cancer Network UK
- Liver4Life
- LIVErNORTH
- Lobular Breast Cancer
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- METUPUK
- OG Support
- OPA Cancer Charity Oesophageal and Gastric Support
- Oncogene-Driven Lung Cancer Patient Alliance UK
- Oncogene Cancer Research
- Orchid
- Ovacome
- Ovarian Cancer Action
- Pancreatic Cancer Action
- Pancreatic Cancer UK
- PCaSO Prostate Cancer Support Organisation
- Pelican Cancer Foundation
- Prevent Breast Cancer
- Prostate Cancer Research
- Prostate Matters
- Robin Cancer Trust
- Roy Casle Lung Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tackle Prostate Cancer
- Target Ovarian Cancer
- Tenovus Cancer Care
- United Kingdom Lung Cancer Coalition
- Professional groups
- Association of Cancer Physicians
- British Geriatrics Society
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- Cancer Research UK
- Cholangiocarcinoma UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 October 2025 | Invitation to participate |
| 02 October 2025 | To appraise the clinical and cost effectiveness of Catumaxomab within its marketing authorisation for treating malignant ascites ID6580 |
| 25 July 2025 - 22 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6580 |
| 25 July 2025 | In progress. Scoping commencing |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual